BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17897973)

  • 21. How tobacco-friendly science escapes scrutiny in the courtroom.
    Friedman LC; Daynard RA; Banthin CN
    Am J Public Health; 2005; 95 Suppl 1():S16-20. PubMed ID: 16030332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economics on trial: the use and abuse of economic methods in third party tobacco litigation.
    Max W; Tsoukalas T
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv77-83. PubMed ID: 17130627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA's misplaced priorities: premarket review under the Family Smoking Prevention and Tobacco Control Act.
    Jenson D; Lester J; Berman ML
    Tob Control; 2016 May; 25(3):246-53. PubMed ID: 27068243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tobacco control implications of the first European product liability suit.
    Hiilamo HT
    Tob Control; 2005 Feb; 14(1):22-30. PubMed ID: 15735296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting youth and concerned smokers: evidence from Canadian tobacco industry documents.
    Pollay RW
    Tob Control; 2000 Jun; 9(2):136-47. PubMed ID: 10841849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tobacco and the law: the state of the art.
    Howard G
    Br Med Bull; 1996 Jan; 52(1):143-56. PubMed ID: 8746303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smoking, disease, and obdurate denial: the Australian tobacco industry in the 1980s.
    Carter SM; Chapman S
    Tob Control; 2003 Dec; 12 Suppl 3(Suppl 3):iii23-30. PubMed ID: 14645945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenging the epidemiologic evidence on passive smoking: tactics of tobacco industry expert witnesses.
    Francis JA; Shea AK; Samet JM
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv68-76. PubMed ID: 17130626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Tobacco Industry's Abuse of Scientific Evidence and Activities to Recruit Scientists During Tobacco Litigation.
    Lee S
    J Prev Med Public Health; 2016 Jan; 49(1):23-34. PubMed ID: 26841882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobacco industry efforts subverting International Agency for Research on Cancer's second-hand smoke study.
    Ong EK; Glantz SA
    Lancet; 2000 Apr; 355(9211):1253-9. PubMed ID: 10770318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The divergence between scientific and legal approaches concerning the cause of effects of tobacco use under Spanish law.
    Arcos Vieira ML
    Med Law; 2010 Jun; 29(2):171-82. PubMed ID: 22462282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meanings & motives. Experts debating tobacco addiction.
    Mars SG; Ling PM
    Am J Public Health; 2008 Oct; 98(10):1793-802. PubMed ID: 18703459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobacco companies protest about federal court ruling on corrective statements.
    Dyer O
    BMJ; 2014 Oct; 349():g6067. PubMed ID: 25288388
    [No Abstract]   [Full Text] [Related]  

  • 34. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial.
    Hurt RD; Robertson CR
    JAMA; 1998 Oct; 280(13):1173-81. PubMed ID: 9777818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cigarette controversy.
    Cummings KM; Brown A; O'Connor R
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1070-6. PubMed ID: 17548665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethical implications of physician involvement in lawsuits on behalf of the tobacco industry.
    Alderman J
    J Law Med Ethics; 2007; 35(4):692-8, 513. PubMed ID: 18076519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobacco industry attempts to frame smoking as a 'disability' under the 1990 Americans with Disabilities Act.
    van der Eijk Y; Glantz SA
    PLoS One; 2017; 12(11):e0188188. PubMed ID: 29176829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Premiere example of the illusion of harm reduction cigarettes in the 1990s.
    Pollay RW; Dewhirst T
    Tob Control; 2003 Sep; 12(3):322-32. PubMed ID: 12958396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tobacco industry lawyers as "disease vectors".
    Guardino SD; Daynard RA
    Tob Control; 2007 Aug; 16(4):224-8. PubMed ID: 17652236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Learning from Philip Morris: Japan Tobacco's strategies regarding evidence of tobacco health harms as revealed in internal documents from the American tobacco industry.
    Iida K; Proctor RN
    Lancet; 2004 May; 363(9423):1820-4. PubMed ID: 15172783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.